Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Numinus Wellness Inc. (T:NUMI)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
Company Contact
Address: 393 Laurier Ave W
Tel: N/A
IR: See website
Key People
Payton Nyquvest
Chairman of the Board, Chief Executive Officer
Michael Tan
President, Chief Operating Officer, Director
Melony Valleau
Interim Chief Financial Officer
Paul Thielking
Chief Scientific Officer, Chief Medical Officer
Devon Christie
Medical Director and Member of Clinical Advisory Council
Business Overview
Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.
Financial Overview
For the six months ended 29 February 2024, Numinus Wellness Inc revenues remained flat at C$11M. Net loss decreased 24% to C$10.4M. Revenues reflect Clinical research operations segment increase of 36% to C$1.8M, Canadian clinic network segment increase of 5% to C$1.6M, Canada segment increase of 5% to C$1.6M, also reflect US Clinic Network segment decrease of 7% to C$7.6M, United States segment decrease of 1% to C$9.4M.
Reporting Currency: Canadian Dollars
Enterprise value: $12.86M as of May 31, 2024
Annual revenue (TTM): $23.14M as of May 31, 2024
EBITDA (TTM): -$19.71M as of May 31, 2024
Net annual income (TTM): -$26.99M as of May 31, 2024
Free cash flow (TTM): -$17.26M as of May 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 316,455,100 as of Mar 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization